Facebook
Twitter
LinkedIn
ForwardPulse - What the Pox - A Review of Therapies for MPOX Treatment and Prevention
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
The 2022 outbreak of monkeypox (mpox) represents a significant public health challenge. In order to navigate this challenge, pharmacists, other healthcare providers, and policymakers must have an appreciable understanding of the history of poxvirus diseases, investigational therapeutics for monkeypox, and recommended treatment and prevention options, as well as health inequities that surround monkeypox and mirror those of previous epidemics. Lessons learned from this important outbreak event can be used to respond to future outbreaks of infectious disease. This presentation focuses on the evidence regarding medication therapies for mpox infection including tecovirimat, cidofovir, brincidofovir, and VIGIV as well as prophylactic vaccinations for smallpox and mpox.
Target Audience
Pharmacist
Learning Objectives
Identify connections between the most recent mpox epidemic and the history of smallpox
Describe clinical features of and treatment options for mpox
Discuss prophylactic therapies effective for mpox prevention
Additional Information
| Attachment | Size |
|---|---|
 Audience Disclosure slide_AG.pptx | 913.73 KB |
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
The 2022 outbreak of monkeypox (mpox) represents a significant public health challenge. In order to navigate this challenge, pharmacists, other healthcare providers, and policymakers must have an appreciable understanding of the history of poxvirus diseases, investigational therapeutics for monkeypox, and recommended treatment and prevention options, as well as health inequities that surround monkeypox and mirror those of previous epidemics. Lessons learned from this important outbreak event can be used to respond to future outbreaks of infectious disease. This presentation focuses on the evidence regarding medication therapies for mpox infection including tecovirimat, cidofovir, brincidofovir, and VIGIV as well as prophylactic vaccinations for smallpox and mpox.
Hannah Madara, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.